Choreo LLC Sells 1,549 Shares of Humana Inc. (NYSE:HUM)

Key Points

• Choreo LLC has reduced its stake in Humana Inc. by 23.1%, holding 5,162 shares worth approximately $1,371,000 following the sale of 1,549 shares in Q1.
• Despite Choreo's decrease, other investors such as Dodge & Cox and GAMMA Investing LLC have significantly increased their positions in Humana, which indicates notable interest from hedge funds in the company.
• Humana recently reported an EPS of $11.58 for the quarter, outperforming analyst expectations, with a revenue increase of 8.4% year-over-year, signaling strong financial performance.

Choreo LLC lessened its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 23.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 5,162 shares of the insurance provider's stock after selling 1,549 shares during the period. Choreo LLC's holdings in Humana were worth $1,371,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of HUM. Riverview Trust Co purchased a new stake in Humana in the 1st quarter worth about $34,000. Garde Capital Inc. purchased a new stake in Humana in the 1st quarter worth about $36,000. Transce3nd LLC purchased a new stake in Humana in the 4th quarter worth about $38,000. Whipplewood Advisors LLC lifted its stake in Humana by 639.1% in the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after acquiring an additional 147 shares in the last quarter. Finally, Colonial Trust Advisors raised its holdings in shares of Humana by 4,500.0% during the fourth quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider's stock worth $47,000 after acquiring an additional 180 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on HUM. Bank of America cut their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a report on Tuesday, June 17th. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a report on Thursday, May 1st. Wells Fargo & Company set a $348.00 price objective on Humana in a report on Friday, July 18th. Barclays set a $268.00 price objective on Humana and gave the stock an "equal weight" rating in a report on Thursday, June 12th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Sixteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Humana has an average rating of "Hold" and a consensus price target of $282.43.

Humana Stock Performance

Shares of NYSE:HUM traded up $3.63 during midday trading on Tuesday, hitting $235.15. The company's stock had a trading volume of 501,850 shares, compared to its average volume of 1,697,102. The stock has a market capitalization of $28.38 billion, a price-to-earnings ratio of 16.61, a PEG ratio of 1.63 and a beta of 0.44. The stock's 50 day simple moving average is $234.25 and its 200 day simple moving average is $255.84. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $406.09. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. During the same quarter last year, the company earned $7.23 earnings per share. The firm's revenue was up 8.4% on a year-over-year basis. As a group, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.